argenx announces Annual General Meeting of Shareholders on May 6, 2026

Rhea-AI Summary

argenx (Euronext & Nasdaq: ARGX) announced its Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol.

Agenda items include adoption of the 2025 annual accounts, advisory vote on the 2025 remuneration report, discharge of directors, share issuance authorization and several board appointments and reappointments. Documents and e-voting information are available on the argenx website and via ABN AMRO e-voting; shareholders are encouraged to vote by proxy. For copies contact legal@argenx.com.

News Market Reaction – ARGX

+2.70%

+2.70% Session close to close

In the Mar 23 session, ARGX gained 2.70%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement centers on the 2026 Annual General Meeting, including standard items such as adopt...

Analysis

This announcement centers on the 2026 Annual General Meeting, including standard items such as adoption of the 2025 accounts, a vote on the remuneration report, director discharges and renewed share issuance authorities. It also outlines planned board refreshment and the retirement of a long-serving non-executive director. In light of recent strong financial and clinical disclosures, investors may watch how leadership transitions, capital authorization renewals and future AGM outcomes intersect with the company’s broader growth plans.

Key Figures

AGM date: May 6, 2026 AGM time: 13:00 CET Executive director term: 4 years +3 more

6 metrics

AGM date May 6, 2026 Scheduled Annual General Meeting of shareholders

AGM time 13:00 CET Start time of Annual General Meeting

Executive director term 4 years Proposed term for Karen Massey as executive director

Non-executive director terms 4 years Proposed terms for several non-executive directors

Non-executive director term 2 years Proposed term for Pamela Klein as non-executive director

Service since May 2018 Jim Daly’s tenure as non-executive director

Historical Context

5 past events · Latest: Mar 06 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 06	Conference data preview	Positive	-1.4%	Preview of VYVGART and pipeline data for 2026 AAN meeting.
Feb 26	Full-year 2025 earnings	Positive	-5.6%	Strong 2025 results with first operating profitability and pipeline updates.
Feb 26	Phase 3 trial success	Positive	-5.6%	Positive Phase 3 ADAPT OCULUS topline results in ocular myasthenia gravis.
Feb 23	Conference participation	Neutral	-2.1%	Announcement of fireside chat at TD Cowen healthcare conference.
Feb 19	Earnings date notice	Neutral	+0.2%	Scheduling of full-year 2025 results and Q4 business update.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent positive clinical and financial updates have been followed by negative price reactions, indicating a pattern of selling into good news.

Recent Company History

Over recent months, argenx has reported strong 2025 financials, including its first operating profit year, and positive Phase 3 ADAPT OCULUS data in ocular myasthenia gravis. It also highlighted upcoming data at the 2026 AAN meeting and maintained active investor outreach via conferences and scheduled earnings events. Despite fundamentally positive milestones, several of these announcements (on Feb 23, Feb 26 and Mar 6) were followed by share price declines, showing a tendency for the stock to trade lower after good news.

Key Terms

proxy, e-voting system, board of directors, non-executive director, +2 more

6 terms

proxy financial

"information on attending the meeting in person or by proxy, requirements for"

A proxy is the authorization a shareholder gives to another person or document to cast votes on their behalf at a company meeting. Think of it like handing someone your voting ticket so they can represent your choices on board elections, executive pay, mergers and other big decisions; it matters because proxies determine who controls the company and which proposals pass, directly affecting share value and investor returns.

e-voting system technical

"requirements for notification and registration for the meeting and regarding the e-voting system"

An e-voting system is an electronic platform that lets shareholders cast and record votes on corporate matters—such as board elections and mergers—using computers or mobile devices instead of paper ballots. It matters to investors because voting determines who makes key decisions that affect a company’s strategy and value; the system’s ease of use, security and auditability influence turnout, the fairness of outcomes and investors’ confidence in corporate governance, much like online banking replaces paper checks but must be trusted.

board of directors regulatory

"authorization of the Board of Directors to issue shares and to limit"

The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.

non-executive director regulatory

"Appointment of Tim Van Hauwermeiren as non-executive director to the Board"

A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.

remuneration report financial

"an advisory vote on the company’s 2025 remuneration report, the discharge of"

A remuneration report is a formal disclosure that lists how much company leaders and board members are paid, including salaries, bonuses, stock awards, pension and other benefits, and explains the rules used to set that pay. Investors use it like a receipt or scorecard to judge whether management’s incentives are aligned with shareholder interests, to estimate ongoing costs, and to spot governance or risk issues that could affect a stock’s value.

pre-emptive rights financial

"to issue shares and to limit or exclude pre-emptive rights in relation thereto"

An investor's pre-emptive rights are the option given to existing shareholders to buy new shares before they are offered to the public or new investors, letting them maintain their percentage ownership and voting power. Think of it like a right of first refusal at a sale: it prevents ownership from being diluted by allowing current holders to keep the same stake, which matters because dilution can reduce influence and the share of future profits.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

March 20, 2026

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Annual General Meeting of shareholders will be held at 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701, 1118 BN Schiphol, the Netherlands.

The shareholders and all other persons with meeting rights are invited to attend the Annual General Meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.

Agenda
In addition to recurrent items on the agenda, such as the discussion and adoption of the 2025 annual accounts, an advisory vote on the company’s 2025 remuneration report, the discharge of the directors for their duties performed in 2025 and the authorization of the Board of Directors to issue shares and to limit or exclude pre-emptive rights in relation thereto, the following changes to the Board of Directors are also proposed:

• Appointment of Karen Massey as executive director to the Board for a term of 4 years
• Appointment of Tim Van Hauwermeiren as non-executive director to the Board for a term of 4 years
• Re-appointment of Ana Céspedes as non-executive director to the Board of Directors for a term of 4 years
• Re-appointment of Camilla Sylvest as non-executive director to the Board of Directors for a term of 4 years
• Re-appointment of Pamela Klein as a non-executive director to the Board of Directors for a term of 2 years
  
  

Jim Daly to retire as non-executive director and Chair of the Commercialization Committee, effective May 6, 2026
Mr. Daly has served as a non-executive director since May 2018. The Board of Directors is currently examining the options for succession of Jim Daly as Chair of the Commercialization Committee.

“I would like to express my deep gratitude to Jim for his significant contributions during his tenure with argenx. His contributions as Chair of the Commercialization Committee have been instrumental in architecting our commercial operations and guiding us through multiple product launches, while supporting our entrepreneurial spirit and commitment to innovation.” commented Mr. Peter Verhaeghe.

The agenda for the meeting as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.

About argenx 
argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

For further information, please contact:  

Media:

Ben Petok
bpetok@argenx.com

Investors:

Alexandra Roy  
aroy@argenx.com 

FAQ

When and where is argenx's AGM for shareholders (ARGX) scheduled in 2026?

The argenx AGM is scheduled for 13:00 CET on Wednesday, May 6, 2026 at the Hilton Amsterdam Schiphol. According to the company, the meeting location and time are listed in the formal convocation and on the argenx website.

What key agenda items will argenx (ARGX) address at the May 6, 2026 AGM?

Key items include adopting the 2025 annual accounts, an advisory vote on the 2025 remuneration report, discharge of directors, and authorization to issue shares. According to the company, board appointments and reappointments are also proposed on the agenda.

Which board changes are proposed at argenx's ARGX Annual General Meeting on May 6, 2026?

Proposed changes include appointing Karen Massey as executive director and Tim Van Hauwermeiren as non-executive director, plus multiple reappointments. According to the company, terms proposed are generally four years, with one two-year reappointment.

How can ARGX shareholders vote or access meeting documents for the May 6, 2026 AGM?

Shareholders can vote by electronic proxy and access documents via the argenx website and ABN AMRO e-voting. According to the company, the formal convocation details registration, e-voting procedures, and how to obtain copies by emailing legal@argenx.com.

What did argenx announce about Jim Daly in the ARGX May 6, 2026 AGM notice?

Jim Daly will retire as non-executive director and Chair of the Commercialization Committee effective May 6, 2026. According to the company, the board is examining succession options for the Commercialization Committee chair role.